Sinopharm Group Stock Price, News & Analysis (OTCMKTS:SHTDF) $2.47 -0.12 (-4.44%) (As of 12:27 PM ET) Add Compare Share Share Today's Range$2.47▼$2.4750-Day Range$2.38▼$2.9652-Week Range$2.27▼$3.63Volume406 shsAverage Volume6,328 shsMarket CapitalizationN/AP/E Ratio2.48Dividend Yield10.52%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesShort InterestStock AnalysisChartFinancialsHeadlinesShort Interest Sinopharm Group MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.16Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.86 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Sinopharm Group. Previous Next 0.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverSinopharm Group has a short interest ratio ("days to cover") of 554.3, which indicates bearish sentiment.Change versus previous monthShort interest in Sinopharm Group has recently increased by 62.02%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldSinopharm Group pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSinopharm Group does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sinopharm Group is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SHTDF. Previous Next 1.0 News and Social Media Coverage News SentimentSinopharm Group has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sinopharm Group this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sinopharm Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 16.47% of the stock of Sinopharm Group is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sinopharm Group is 2.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Sinopharm Group is 2.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.31. Previous Next See Top Rated MarketRank™ Stocks Here About Sinopharm Group Stock (OTCMKTS:SHTDF)Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.Read More SHTDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SHTDF Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comSinopharm Group (OTCMKTS:SHTDF) Shares Pass Below 200 Day Moving Average of $2.94November 8, 2023 | morningstar.comSinopharm Group Co Ltd SHTDFNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 12, 2023 | msn.comSinopharm Group (HKEX:1099) Price Target Increased by 8.31% to 29.48April 13, 2023 | finance.yahoo.comPfizer signs strategic cooperation pact with China's SinopharmApril 6, 2023 | msn.comWHO chief expects COVID emergency to end this yearMarch 24, 2023 | msn.comChina approves its first mRNA Covid-19 vaccineMarch 22, 2023 | news.yahoo.comChina approves first home-grown mRNA Covid vaccineNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comFebruary 23, 2023 | forbes.comSinopharm GroupJanuary 20, 2023 | news.yahoo.comSinopharm unit gets OK for clinical trials of mRNA COVID vaccineJanuary 20, 2023 | msn.comPharma major Sinopharm gets approval for clinical trials of mRNA Covid-19 vaccineDecember 8, 2022 | reuters.comSinopharm's second Chinese herb shot is potentDecember 2, 2022 | seekingalpha.comVaxxinity says COVID vaccine outperformed Astra and Sinopharm shots as boosterSeptember 28, 2022 | seekingalpha.comMerck in pact with Sinopharm to launch oral COVID-19 therapy in ChinaSeptember 15, 2022 | msn.comSinopharm to boost local COVID vaccine production in AfricaSeptember 7, 2022 | msn.comChina’s Sinovac to test Omicron-targeting vaccines in ChileJuly 27, 2022 | msn.comDaesang to set up joint venture with China Sinopharm InternationalJuly 17, 2022 | seekingalpha.comWeek In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology InvestmentsJuly 4, 2022 | msn.comHong Kong could have 3 Omicron-targeting jabs by end of year, as health expert reveals Sinopharm hopes to make new vaccine available by DecemberJune 27, 2022 | msn.comChina Donates 10 Mil Doses of Sinopharm COVID-19 Vaccines, SyringesJune 22, 2022 | usnews.comSome Omicron Sub-Variants Escaping Antibodies From Sinopharm Shot -Chinese StudyJune 21, 2022 | reuters.comSome Omicron sub-variants escaping antibodies from Sinopharm shot - Chinese studyMay 31, 2022 | msn.comUniversity of Hong Kong, Sinopharm launch city’s first trial for Omicron-targeting vaccine which could be ready in NovemberMay 28, 2022 | seekingalpha.comCanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?April 18, 2022 | seekingalpha.comSinovac Biotech's Omicron-specific vaccine cleared for clinical trial in Hong KongApril 16, 2022 | msn.comSinopharm, Sinovac vaccine candidates for Omicron variant gets clearance for clinical trialSee More Headlines Receive SHTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sinopharm Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medical Distribution Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SHTDF CUSIPN/A CIK1556605 Webir.sinopharmgroup.com.cn Phone86-21-2305-2666FaxN/AEmployees114,766Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio2.48 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Qingming Yu (Age 59)Executive Chairman of the Board Comp: $888.91kMr. Yong Liu (Age 54)President & Executive Director Comp: $859.6kMs. Xiaojuan Li (Age 47)Chief Financial Officer Mr. Yijian Wu (Age 53)Secretary to the Board, Company Secretary & Authorised Representative Key CompetitorsAlfresaOTC:ARHCFArjo AB (publ)OTCMKTS:ARRJFEBOS GroupOTCMKTS:EBOSFGalenicaOTCMKTS:GALNFMcKesson EuropeOTCMKTS:CAKFYView All Competitors SHTDF Stock Analysis - Frequently Asked Questions How have SHTDF shares performed in 2023? Sinopharm Group's stock was trading at $2.53 at the beginning of the year. Since then, SHTDF shares have decreased by 2.3% and is now trading at $2.4725. View the best growth stocks for 2023 here. Are investors shorting Sinopharm Group? Sinopharm Group saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,438,900 shares, an increase of 62.0% from the October 31st total of 1,505,300 shares. Based on an average trading volume of 4,400 shares, the short-interest ratio is presently 554.3 days. View Sinopharm Group's Short Interest. Is Sinopharm Group a good dividend stock? Sinopharm Group (OTCMKTS:SHTDF) pays an annual dividend of $0.26 per share and currently has a dividend yield of 1.11%. The dividend payout ratio is 26.05%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Sinopharm Group? Shares of SHTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:SHTDF) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinopharm Group Co. Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.